Indoleamine-2,3-dioxygenase 1/cyclooxygenase 2 expression prediction for adverse prognosis in colorectal cancer

Table 2 Correlation of nuclear indoleamine-2,3-dioxygenase 1 expression with colorectal cancer clinicopathologic parameters

Characteristic	Total	Low IDO1	High IDO1	P-value
Sex				0.70
Male	51	39 (76.5)	12 (33.5)
Female	44	36 (81.8)	8 (19.2)
Age in yr				0.92
> 60	30	24 (80.0)	6 (20.0)
≤ 60	65	51 (78.5)	14 (21.5)
Cancers				0.52
Colon	46	38 (82.6)	18 (17.4)
Rectum	49	37 (75.5)	12 (24.5)
BMI				< 0.001
> 25	20	9 (45.0)	11 (55.0)
≤ 25	75	66 (88.0)	9 (12.0)
Tumor differentiation				0.87
Moderate and poor	78	60 (76.9)	18 (23.1)
Well	17	14 (82.3)	3 (17.7)
Conlon cancer stage				0.98
3	20	17 (85.0)	3 (15.0)
2	26	21 (80.8)	5 (19.2)
T stage				0.71
4	29	23 (19.3)	6 (20.7)
2/3	17	15 (88.2.)	2 (11.8)
N stage				0.98
1/2	20	16 (80.0)	4 (20.0)
0	26	22 (84.6)	4 (15.4)
Rectum cancer stage				0.44
3	24	17 (70.8)	7 (29.2)
2	25	21 (84.0)	4 (16.0)
T stage				0.94
4	22	16 (72.7)	6 (27.3)
2/3	27	21 (77.8)	6 (22.2)
N stage				0.28
1/2	24	16 (66.7)	8 (33.3)
0	25	21(84.0)	4 (16.0)
CEA in ng/mL				0.37
> 5	42	35 (83.3)	7 (16.7)
≤ 5	53	39 (73.6)	14 (26.4)
CA19-9 in U/mL				0.78
> 37	81	41 (50.6)	40 (49.4)
≤ 37	17	8 (47.1)	9 (52.9)
CD3 TILs				0.96
High	36	28 (77.8)	8 (22.2)
Low	59	47 (79.7)	12 (20.3)
CD8 TILs				0.26
High	22	15 (68.2)	7 (31.8)
Low	73	60 (82.2)	13 (17.8)
COX2				0.84
High	48	38 (79.2)	10 (20.8)
Low	47	37 (78.7)	10 (21.3)
Treatment group				0.16
Celecoxib	44	38 (86.4)	6 (13.6)
Non-celecoxib	51	37 (72.5)	14 (27.5)

Data are presented as n or n (%). BMI: Body mass index; CA: Cancer antigen; CEA: Carcinoembryonic antigen; COX2: Cyclooxygenase 2; CRC: Colorectal cancer; IDO1: Indoleamine-2,3-dioxygenase 1; TILs: Tumor-infiltrating lymphocytes.